Seguir
Andres Lanzos
Andres Lanzos
BioMedical Data Scientist
Dirección de correo verificada de runbox.com - Página principal
Título
Citado por
Citado por
Año
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
E Rheinbay, MM Nielsen, F Abascal, JA Wala, O Shapira, G Tiao, ...
Nature 578 (7793), 102-111, 2020
5442020
Hacking the cancer genome: profiling therapeutically actionable long non-coding RNAs using CRISPR-Cas9 screening
R Esposito, N Bosch, A Lanzós, T Polidori, C Pulido-Quetglas, R Johnson
Cancer cell 35 (4), 545-557, 2019
1762019
Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis
J Carlevaro-Fita, A Lanzós, L Feuerbach, C Hong, D Mas-Ponte, ...
Communications Biology 3 (1), 1-16, 2020
1692020
Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features
A Lanzós, J Carlevaro-Fita, L Mularoni, F Reverter, E Palumbo, R Guigó, ...
Scientific Reports. 2017; 7: 41544, 2017
1212017
Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs
A Vancura, A Lanzós, N Bosch-Guiteras, MT Esteban, AH Gutierrez, ...
NAR Cancer 3 (2), zcab013, 2021
222021
Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities
R Esposito, T Polidori, DF Meise, C Pulido-Quetglas, P Chouvardas, ...
Cell genomics 2 (9), 2022
152022
Tumour mutations in long noncoding RNAs enhance cell fitness
R Esposito, A Lanzós, T Uroda, S Ramnarayanan, I Büchi, T Polidori, ...
Nature communications 14 (1), 3342, 2023
62023
EACR Cancer Genomics 2019 conference: from tumour evolution to personalised immunotherapy
A Lanzós, K Elliott
The FEBS journal, 2019
12019
Identifying novel biomarkers with deep proteomics profiling and survival analysis in NSCLC patients treated with anti-PD-1-blockade
E Nguyen, R Poli, K Sklodowski, V Dozio, A Lanzós, K Beeler, E Romano
Annals of Oncology 32, S1382, 2021
2021
Big Proteomic Data from a Digital Biobank Boost the Confidence in Biomarker Discovery
A Lanzós, R Bruderer, J Muntel, L Reiter, O Rinner, S Schegk
ASMS 2021, 2021
2021
Immune-related adverse effects (irAEs) associated proteomic profile in late-stage NSCLC patients after PD-1 blockade
K Sklodowski, V Dozio, R Poli, A Lanzós, S Lopez-Lastra, K Beeler, ...
Cancer Research 81 (13_Supplement), 1615-1615, 2021
2021
Protein signature associated with response and progression free survival in late-stage NSCLC patients treated with anti-PD-1 blockade
E Romano, K Sklodowski, V Dozio, A Lanzós, K Beeler
Annals of Oncology 32, S12, 2021
2021
Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients
K Sklodowski, V Dozio, S Lopez-Lastra, A Lanzós, K Beeler, E Romano
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
2020
Bioinformatic Analysis of Cancer Driver Long Non-coding RNAs
AAL Camaioni
Faculty of Medicine of the University of Bern, 2019
2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–14